PMC10282638_01
Evolution of hemoglobin (Hb), hematocrit (Hct), leukocyte (white blood cells, WBC) and platelets (Plts) count during treatment.
fonc-13-1212638-g001.jpg
PMC10282638_01_fonc-13-1212638-g001.jpg
f1
No hematological or extra-hematological toxicities were reported with ruxolitinib-avelumab combination in the first 5 months of follow-up ( Figure 1 ).